PO.MCB09.02 · 分子与细胞生物学

柠檬酸的胞质转运保护营养严苛的胰腺癌免于铁死亡

Cytosolic transport of citrate protects nutrient-austere pancreatic cancer from ferroptosis

海报缩略图:柠檬酸的胞质转运保护营养严苛的胰腺癌免于铁死亡
编号 7325 展板 11 时间 4/22 09:00–12:00 区域 Section 23 主讲 Adam Kneebone, BA
分会场 Metabolic Vulnerabilities in Pancreatic, Hepatic, and Renal Cancers
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Adam Kneebone1, Kailey Lindaur1, Ata Abbas2, Joel Cassel3, Sarah Graff4, Caudia Rose Keating1, Gerard Abood1, Xianzhong Ding1, William Small5, Clodia Osipo1, Wei Qiu1, Curtis Tatsuoka6, Simone Sidoli4, Costas Andreas Lyssiotis7, Joseph M. Salvino3, Ali Vaziri-Gohar1

1Loyola University Chicago Stritch School of Medicine, Maywood, IL,2Case Western Reserve University, Cleveland, OH,3The Wistar Institute, Philadelphia, PA,4Albert Einstein College of Medicine, New York, NY,5Professor, Loyola University Medical Center, Maywood, IL,6University of Maryland, Baltimore, MD,7University of Michigan, Ann Arbor, MI

摘要 Abstract

中文摘要
胰腺癌(PDAC)细胞在灌注不良的肿瘤微环境中经历营养饥饿。在营养受限的生态位中保护PDAC细胞免于有害氧化应激的代谢依赖性,代表了肿瘤特异性靶点。虽然线粒体在支持细胞能量产生和生物合成需求方面的作用已得到充分研究,但当PDAC细胞暴露于营养剥夺时,线粒体对维持细胞内氧化还原稳态的贡献尚不清楚。我们的结果表明,柠檬酸经SLC25A1的胞质转运在营养受限条件下通过保护PDAC细胞免于铁死亡(一种公认的铁依赖性细胞死亡机制)而赋予其生存优势。使用选择性SLC25A1抑制剂或靶向线粒体OXPHOS显著降低了GPX4表达和PDAC细胞活力。用ACLY和ACO1依赖通路的产物挽救GPX4表达,揭示了它们在代谢应激下赋予生存优势的关键作用。重要的是,外源性表达GPX4逆转了因缺乏SLC25A1活性导致的氧化还原失衡和代谢失调,表明需要柠檬酸诱导的GPX4表达来支持线粒体健康和功能。正如在营养受限的培养细胞中观察到的那样,SLC25A1的功能被证明在胰腺肿瘤微环境中不可或缺,而因缺乏SLC25A1活性导致的生长减少在PDAC临床前模型中可被抗氧化剂NAC挽救。最后,SLC25A1抑制伴随谷氨酰胺代谢升高,且用SLC25A1的药理学抑制剂与谷氨酰胺酶抑制剂CB-839联合治疗显著抑制了肿瘤生长,凸显了这一联合方法作为PDAC潜在治疗策略的价值。
查看英文原文 English abstract
Pancreatic cancer (PDAC) cells experience nutrient starvation in a poorly perfused tumor microenvironment. Metabolic dependencies that protect PDAC cells from detrimental oxidative stress in a nutrient-restricted niche represent as tumor-specific targets. While the role of mitochondria in supporting energy production and biosynthetic requirements of cells has been well investigated, their contribution to maintaining intracellular redox homeostasis when PDAC cells are exposed to nutrient deprivation is unknown. Our results demonstrate that cytosolic transport of citrate via SLC25A1 confers a survival advantage to PDAC cells by protecting them from ferroptosis, a well-established iron-dependent cell death mechanism, under nutrient-limited conditions. Employing selective SLC25A1 inhibitor or targeting mitochondrial OXPHOS dramatically reduced GPX4 expression and PDAC cell viability. Rescuing GPX4 expression with the products of both ACLY and ACO1-dependent pathways uncovered their critical role in conferring survival advantage under metabolic stress. Importantly, exogenous expression of GPX4 reversed redox imbalance and metabolic discordance resulting from the lack of SLC25A1 activity, indicating the requirement of citrate-induced GPX4 expression to support mitochondrial health and function. As observed with cultured cells under nutrient limitation, SLC25A1 function was revealed to be indispensable in pancreatic tumor microenvironment, and the reduced growth, due to the lack of SLC25A1 activity, was rescued with antioxidant NAC in preclinical models of PDAC. Lastly, SLC25A1 suppression was accompanied by elevated glutamine metabolism, and combination therapy with pharmacologic inhibitors of SLC25A1 and glutaminase inhibitor CB-839 dramatically suppressed tumor growth, highlighting this combinatorial approach as a potential therapeutic strategy in PDAC.
利益披露 Disclosure
A. Kneebone, None.. K. Lindaur, None.. A. Abbas, None.. J. Cassel, None.. S. Graff, None.. C. R. Keating, None.. G. Abood, None.. X. Ding, None.. C. Osipo, None.. W. Qiu, None.. C. Tatsuoka, None.. S. Sidoli, None.. A. Vaziri-Gohar, None.

← 返回 AACR 2026 检索